公司资料
Vera Therapeutics 股价、新闻与催化剂
- 股票代码:
- VERA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
31.63 USD (0.00%)
收盘价
最后更新: 2026年8月17日
2.24B USD
市值
股价为何变动
As of Aug 17, 2026, VERA was little changed and closed at $31.63. No new same-company headline was identified in the current news window.
公司概览
Kidney-Disease Biologics
Vera Therapeutics develops therapies for immune-mediated kidney diseases. Its lead program targets B-cell survival signals implicated in abnormal antibody production.
Atacicept
Atacicept is a recombinant TACI fusion protein that binds BAFF and APRIL. It is under Priority Review for accelerated approval in adults with IgA nephropathy.
Commercial Transition
Vera is preparing to move from clinical development into a commercial-stage model centered on atacicept, subject to FDA approval.
未来催化剂
- FDA PDUFA target action date for atacicept on July 7, 2026.
- Potential U.S. launch of atacicept around mid-2026, subject to approval.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。